- Home
- SYRE vs NEO Comparison
SYRE vs NEO Comparison
Compare SYRE & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- NEO
- Stock Information
- Founded
- SYRE 2013
- NEO 2001
- Country
- SYRE United States
- NEO United States
- Employees
- SYRE N/A
- NEO N/A
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- NEO Precision Instruments
- Sector
- SYRE Health Care
- NEO Health Care
- Exchange
- SYRE Nasdaq
- NEO Nasdaq
- Market Cap
- SYRE 1.2B
- NEO 1.2B
- IPO Year
- SYRE 2016
- NEO 1999
- Fundamental
- Price
- SYRE $16.14
- NEO $9.49
- Analyst Decision
- SYRE Strong Buy
- NEO Strong Buy
- Analyst Count
- SYRE 8
- NEO 10
- Target Price
- SYRE $51.50
- NEO $19.78
- AVG Volume (30 Days)
- SYRE 661.8K
- NEO 1.5M
- Earning Date
- SYRE 05-08-2025
- NEO 04-29-2025
- Dividend Yield
- SYRE N/A
- NEO N/A
- EPS Growth
- SYRE N/A
- NEO N/A
- EPS
- SYRE N/A
- NEO N/A
- Revenue
- SYRE N/A
- NEO $660,566,000.00
- Revenue This Year
- SYRE N/A
- NEO $12.89
- Revenue Next Year
- SYRE N/A
- NEO $11.36
- P/E Ratio
- SYRE N/A
- NEO N/A
- Revenue Growth
- SYRE N/A
- NEO 11.65
- 52 Week Low
- SYRE $16.13
- NEO $8.98
- 52 Week High
- SYRE $40.84
- NEO $19.11
- Technical
- Relative Strength Index (RSI)
- SYRE 35.24
- NEO 40.10
- Support Level
- SYRE $16.71
- NEO $9.57
- Resistance Level
- SYRE $18.28
- NEO $10.37
- Average True Range (ATR)
- SYRE 1.21
- NEO 0.56
- MACD
- SYRE -0.03
- NEO 0.12
- Stochastic Oscillator
- SYRE 0.15
- NEO 25.39
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.